XML 18 R7.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Summary of Significant Accounting Policies | 6 Months Ended
--- | ---
Jun. 30, 2018
Accounting Policies [Abstract] |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, revenue from grant awards, the valuation of restricted ordinary shares and the valuation of share-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ materially from those estimates. Net Loss Per Ordinary Share Basic and diluted net loss per ordinary share is determined by dividing net loss attributable to ordinary shareholders by the weighted-average ordinary shares outstanding during the period; in accordance with Accounting Standard Codification (ASC) 260, Earnings per Share. For the periods presented, the ordinary shares underlying the convertible preferred shares and options, and unvested restricted ordinary shares have been excluded from the calculation because they would be anti-dilutive. The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as they would be anti-dilutive:
|  | Six months ended |
|  | June 30, 2018 |  |  | June 30, 2017 |
Options to purchase ordinary shares |  |  | 696,112 |  |  |  | 66,832 |
Preferred shares convertible into ordinary shares |  |  | — |  |  |  | 5,686,667 |
Unvested restricted ordinary shares |  |  | 143,076 |  |  |  | 246,282 |
Unvested restricted stock units |  |  | 36,924 |  |  |  | — |
Warrants |  |  | 19,890 |  |  |  | — |
Total |  |  | 896,002 |  |  |  | 5,999,781 |
Segment Information The Company determines and presents operating segments based on the information that is internally provided to the Chief Executive Officer, Chief Scientific Officer, Chief Financial Officer and Chief Commercial Officer, who together are considered the Company’s chief operating decision maker, in accordance with ASC 280, Segment Reporting. The Company has determined that it operates as a single business segment, which is the development and commercialization of innovative treatments for drug resistant bacterial infections. The distribution of total operating expenses by geographical area was as follows:
|  | Three months ended June 30, |  |  | Six months ended June 30, |
Operating expenses |  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
Ireland |  | $ | 12,811 |  |  | $ | 5,205 |  |  | $ | 22,775 |  |  | $ | 9,674 |
U.S. |  |  | 2,800 |  |  |  | 1,208 |  |  |  | 5,230 |  |  |  | 2,281 |
Total |  | $ | 15,611 |  |  | $ | 6,413 |  |  | $ | 28,005 |  |  | $ | 11,955 |
The distribution of long-lived assets by geographical area was as follows:
Long lived assets |  | June 30, 2018 |  |  | December 31, 2017 |
Ireland |  | $ | 3,388 |  |  | $ | 2,341 |
U.S. |  |  | 369 |  |  |  | 243 |
Total |  | $ | 3,757 |  |  | $ | 2,584 |
Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (FASB) issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815), I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred shares that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is required to be adopted for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of ASU 2017-11 is not expected to have a significant impact on the consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 was issued to increase transparency and comparability among entities by recognizing lease assets and lease liabilities on the consolidated balance sheet and disclosing key information about lease arrangements. ASU 2016-02 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of adopting ASU 2016-02 on the consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all significant accounting policies of the reporting entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_SignificantAccountingPoliciesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration